Scancell has announced the appointment of Dr Ursula Ney as a non-executive director of the company with immediate effect, replacing Dr Matthew Frohn who is standing down on 31 October 2019 after more than twelve years of service.

Dr Ney has over thirty years’ experience in the pharmaceutical and biotechnology industry, including twenty years in senior leadership roles that also encompassed executive and non-executive board positions. Her early career was spent at Sandoz and Roche, and she has a PhD from the Royal Free Hospital Medical School and an MBA from Middlesex University Business School.

Dr John Chiplin, chairman of Scancell, said: “I am pleased to welcome Ursula to the Board of Scancell. Ursula’s extensive late stage development experience in the biotech sector will be invaluable as the Company continues to develop its product pipeline. I’d also like to take this opportunity to thank Matthew Frohn for the invaluable contributions he has made to the Company since he was first appointed to the Board in 2006. We wish him well in his future endeavours.”